Enhabit, Inc.

$ 13.80 0.07 %

Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit provides tailored disease-specific plans for individuals with diabetes, congestive heart failure, those recovering from orthopedic surgery or injuries, and patients with respiratory illnesses. Complementing these medical offerings, licensed physical, occupational, and speech therapists deliver vital rehabilitative support. Beyond home health, Enhabit delivers extensive hospice services designed to meet the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. These services encompass pain and symptom control, palliative and dietary counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit maintained a significant operational footprint, with 252 home health agencies and 99 hospice agencies spread across 34 states. Established in 2014 and headquartered in Dallas, Texas, the company was previously known as Encompass Health Home Health Holdings, Inc., officially rebranding to Enhabit, Inc. in March 2022. Enhabit, Inc. began operating as a completely independent entity on July 1, 2022.

CEO: Barbara Ann Jacobsmeyer - https://www.ehab.com

Price objectif

$13.53 -1.96 %

Recommandation

Hold

DCF

$ 6.23

Loading data...

EHAB vs S&P500

Loading data...

No data available.

Quick ratio

1.56

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-197.14

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.07

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-0.58 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-1.58 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.87

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.58

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
1.94 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.37 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.41 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.